Study of OB-002 in Patients With Refractory Metastatic Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Cancer|Metastatic Colorectal Cancer|Metastatic Pancreatic Cancer|Metastatic Gastric Cancer|Metastatic Breast Cancer|Metastatic Urothelial Carcinoma
Interventions: DRUG: OB-002
Sponsor: Orion Biotechnology Polska Sp. z o.o.